ArticlePaediatrics & child health2011
Variation in captopril formulations in pharmacies across Canada.
Article in Paediatrics & child health, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Captopril, an angiotensin-converting enzyme inhibitor used to manage congestive heart failure in the paediatric population, has limited data on efficacy and safety. Its variety of liquid formulations dispensed by different pharmacies poses a challenge in optimizing captopril dosing in patients. Fourteen tertiary paediatric centre pharmacies across Canada were contacted to decipher the type of captopril formulation they dispense, their recipe and the stability of each formulation. Of the 14 centres surveyed, four dispensed solid tablets, two dispensed either solid tablets or liquid formulations, and eight dispensed extemporaneously prepared liquid formulations. There was also great variety in the solutions used to prepare the liquid formulations. The bioequivalence of these preparations has not been studied. As a result, physicians cannot be certain about the effective dose of captopril. Uniformity is recommended among paediatric pharmacies in Canada when preparing medications such as captopril. Proper testing of the stability and bioequivalence of medications is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.